Overview
The aim of this study is to examine the possible clinical effects associated with vitamin K supplementation on the glycemic control, insulin sensitivity and lipid profile of type II diabetic patients.
Eligibility
Inclusion Criteria:
- Adult patients 21-65 years old diagnosed with Type II diabetes.
- Fasting blood glucose concentration 126 mg/dL .
- Normal liver Function tests defined as ALT levels up to 33 U/L for males and up to 25 U/L for females, Albumin levels 3.5 g/dL, Bilirubin up to 1.1 mg/dL .
- Normal clotting function defined as defined by INR.
- Normal kidney function defined as serum creatinine values up to 1.3 mg/dL.
Exclusion Criteria:
- Type I diabetic patients.
- Use of supplements with potential effect on vitamin K level namely supplements containing vitamin K, co-enzyme Q10 or vitamin E > 400 IU .
- Patients requiring anti-coagulant therapy including patients with prosthetic valves, mitral tissues, DVT, PE, atrial fibrillation and valvular heart disease.
- Patient with history of coagulation, MI, stroke and embolization.
- Pregnant or breast feeding women.
- Being on hormonal therapy or receiving contraceptive pills.
- Patients treated with glucocorticoids, thiazide diuretics, and atypical antipsychotics.
- Patients on cholestyramine, antibiotics and coumarins.
- Patients on lipid lowering agents.
- Known intestinal malabsorption syndrome, cholestasis or steatorrhea.
- Smokers.